Arrowhead Pharmaceuticals (ARWR) Operating Leases (2019 - 2026)

Arrowhead Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $107.9 million for Q1 2026.

• Quarterly Operating Leases fell 5.63% year-over-year to $107.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.9 million (down 5.63% YoY) and the FY2025 annual result came in at $104.1 million, down 6.23% from the prior year.
• Operating Leases was $107.9 million for Q1 2026 at Arrowhead Pharmaceuticals, up from $102.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $118.1 million in Q2 2024 and bottomed at $22.7 million in Q1 2022.
• A 5-year average of $96.7 million and a median of $104.6 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases jumped 265.22% — and 2025, when it declined 11.85%.
• Arrowhead Pharmaceuticals' Operating Leases stood at $82.1 million in 2022, then jumped by 40.21% to $115.2 million in 2023, then rose by 0.61% to $115.9 million in 2024, then dropped by 11.85% to $102.1 million in 2025, then climbed by 5.63% to $107.9 million in 2026.
• Business Quant data shows ARWR's Operating Leases at $107.9 million in Q1 2026, $102.1 million in Q4 2025, and $104.1 million in Q3 2025.